Saturday, October 10, 2026 delayed
🦉 Morning. The last day's chatter has settled, and a few names floated to the top. Here's what drew the crowd.
How to read each name below: first line = how morningowl sentiment moved since yesterday, second = where it stands now (-100 to +100).
Provides investment banking advisory services for mergers, acquisitions, restructurings, and valuations.
Each group's sentiment and how much it drove today's overall move:
Analyst sentiment +93; led today's move.
News sentiment +94; added to it.
Analyst commentary centers on Citizens lifting its rating from Market Perform to a more favorable stance, with a price target of $175, citing a valuation well below historical levels. News commentary echoes the same upgrade, adding that shares jumped about 4.1% and that Citizens pointed to record second-quarter backlog and new business plus an improving outlook in financial restructuring and valuation advisory. Both groups align closely, favorable in tone and anchored to the same Citizens call, with the news side supplying the operational detail behind the shift.
As of 2026-10-09, Houlihan Lokey shows a P/E of 22.4, with its last close at the 52.4 percentile of its trailing three-month range and the 13.1 percentile of its twelve-month range, down 4.3% over the past month. Over the last 90 days, open-market insider transactions netted a purchase of about $360,420 (excludes option exercises and awards). Analyst opinion, as of 2026-09-01, splits evenly across seven favorable and seven neutral. It is scheduled to report earnings on 2026-10-28.
Provides wireless, broadband, and fiber-optic communication services to consumers and businesses.
Each group's sentiment and how much it drove today's overall move:
News sentiment -39; led today's move, on unusually heavy chatter.
Analyst sentiment -59; added to it.
Retail sentiment -12; added to it, on unusually heavy chatter.
News commentary centered on SpaceX's roughly $8 billion deal for Grain Management's 800 MHz spectrum portfolio, framing it as a fresh competitive threat that sent AT&T sharply lower alongside Verizon and T-Mobile. Analyst commentary echoed that same catalyst, with Scotiabank reiterating a Sector Perform stance and trimming its price target to $26 from $28. Retail chatter fixated on the same spectrum news and the "space phone" debate, with some doubting SpaceX can dent the big three while others cast satellite service as the future and flagged the sector as one to avoid for now. All three groups converged on the SpaceX spectrum deal as the driver, differing mainly in how seriously retail takes the long-term threat.
As of 2026-10-09, AT&T carried a P/E of 7.3, while its last close sat at the 11.1 percentile of its trailing 3-month range and the 9.9 percentile of its 12-month range, down 12.2% over the past month. It is scheduled to report earnings on 2026-10-21. As of 2026-09-01, coverage leaned favorable across 35 analysts, with 20 favorable, 14 neutral, and 1 cautious.
Provides a cloud-based observability and security platform for monitoring applications and infrastructure.
Each group's sentiment and how much it drove today's overall move:
Analyst sentiment +93; led today's move.
News sentiment +71; added to it, on unusually heavy chatter.
Retail sentiment +43; added to it, on unusually heavy chatter.
Analyst commentary centered on CIBC's reiterated favorable rating and its price target lift to $315 from $280. News coverage tied the roughly 6.6% intraday jump to that CIBC call, set against a broader rebound in AI names and Datadog's recent addition to a list of new mutual-fund holdings. Retail chatter, running unusually heavy, focused on the rally itself, flagging a breakout to all-time highs and talk of institutional accumulation in software. All three groups pointed the same direction, converging on cloud-monitoring demand and the CIBC catalyst as reasons behind the move.
As of 2026-10-09, Datadog carried a P/E of 590.1, and its last close sat at the 100.0 percentile of both its trailing 3-month and 12-month ranges, up 32.3% over the past month. As of 2026-09-01, coverage leans favorable, with 51 favorable, 4 neutral, and 1 cautious among analysts. The company is scheduled to report earnings on 2026-11-05, as of 2026-10-10.
Operates a visual discovery platform where users find, save, and shop ideas like recipes and home inspiration.
Each group's sentiment and how much it drove today's overall move:
Retail sentiment +77; led today's move, on unusually heavy chatter.
News sentiment +43; added to it.
Retail commentary is upbeat and momentum-driven, with traders cheering gains, eyeing a move toward $23, and flagging advertising activity as a positive sign for a solid finish to the year and beyond. News commentary frames Pinterest's roughly 3% climb within a broader social media rally, noting Snap jumped 7% while Meta held flat. Both groups lean favorable, though retail focuses on the stock's own trajectory and targets while news situates the move as part of a sector-wide lift with no company-specific catalyst named.
As of October 9, 2026, Pinterest carried a P/E of 48.8, with its last close at the 44.4 percentile of its trailing three-month range and the 48.0 percentile of its twelve-month range, up 14.0% over the past month. The company is scheduled to report earnings on November 4, 2026. As of September 1, 2026, analyst opinion leaned favorable, with 24 favorable and 21 neutral across 45 analysts.
Develops messenger RNA medicines, including vaccines and therapeutics, for infectious diseases, oncology, and rare conditions.
Each group's sentiment and how much it drove today's overall move:
News sentiment +68; added to it.
Analyst sentiment +94; led today's move.
Retail sentiment +35; added to it, on unusually heavy chatter.
News commentary centered on Moderna's cluster of catalysts, a Nasdaq-100 reentry coinciding with a New York Times report of an NIH-backed personalized cancer-vaccine push and a price target hike, though one article flagged caution at current levels. Analyst commentary was favorable, framing the roughly 14% advance to a fresh 52-week high. Retail chatter, unusually heavy, echoed the same vaccine optimism and pointed to an FDA advisory panel endorsement for Moderna's influenza vaccine plus firm technical momentum, while acknowledging ongoing net losses and valuation scrutiny. All three groups align on the cancer-vaccine initiative as the driver; news and retail both temper the enthusiasm with valuation and profitability concerns, whereas analyst commentary stayed squarely positive.
As of 2026-10-09, Moderna's last close sat at the 100.0 percentile of its trailing three-month range and the 100.0 percentile of its 12-month range, having risen 64.7% over the past month, placing it at the top of both ranges. Across 30 analysts as of 2026-09-01, opinion leans neutral, 11 favorable, 17 neutral, and 2 cautious. It is scheduled to report earnings on 2026-10-29.
That's a wrap for today's chatter, same five, same drama, new day tomorrow. ☕🦉
This is not investment advice. morningowl is a publisher, not a registered investment adviser. We may hold positions in any security mentioned. Past performance and historical commentary patterns do not predict future results. Our data and analysis are provided "as is" and may contain inaccuracies; we accept no liability for errors or for any decisions made in reliance on them.